Positive Japanese data could lead to istradefylline's first approval
This article was originally published in Scrip
Kyowa Hakko Kirin's troubled Parkinson's disease drug istradefylline (KW-6002) is moving towards an approval filing in Japan after meeting its primary endpoint in a local Phase III study.
You may also be interested in...
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.